Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Proteção contra a desinformação sobre vacinas contra o HIV entre meninas adolescentes e mulheres jovens na África do Sul (PROTECT)

28 de agosto de 2026 atualizado por: University of Pennsylvania

Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes. The ongoing susceptibility of young women to HIV infection and the sub-optimal uptake of prevention options such as Pre-Exposure Prophylaxis (PrEP) that are highly effective creates a need for an HIV vaccine to benefit populations at substantial risk of HIV infection. However, lessons from previous vaccine studies and the recent COVID-19 vaccine have highlighted significant barriers to vaccine uptake, such as widespread misinformation and vaccine hesitancy. These challenges threaten the successful implementation of a future HIV vaccine. Building on these insights, this study will utilise psychological inoculation theory to develop and evaluate HIV vaccine messages among adolescent girls and young women. Primary objective: To compare changes in intentions to receive HIV vaccine following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.

Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about the HIV vaccine in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

2163

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Johannesburg, África do Sul
        • Health Economics and Epidemiology Research Office, University of the Witwatersrand

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 29 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Female
  • Age 18-29 years
  • Self-reported history of sexual activity in the past 12 months
  • Self-reported HIV-negative status or unknown HIV status at enrolment
  • Willing and able to provide written informed consent
  • Able to read and understand English

Exclusion Criteria:

  • Unwilling or unable to provide consent for study participation.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Control

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Outro: Enhanced inoculation message

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
HIV Vaccine Intention, at the End of the Baseline Assessment
Prazo: At the end of the baseline assessment

Intention to get the HIV vaccine, measured after inoculation intervention and misinformation exposure The intention to get the vaccine will be measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

At the end of the baseline assessment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
HIV Vaccine Intention, Follow-up
Prazo: 2-4 weeks

Intention to get the HIV vaccine, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

2-4 weeks
Recommend to Friends, at the End of the Baseline Assessment
Prazo: At the end of the baseline assessment

Intention to recommend the HIV vaccine to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

At the end of the baseline assessment
Recommend to Friends, Follow-up
Prazo: 2-4 weeks

Intention to recommend the HIV vaccine to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

2-4 weeks
Credibility of Inoculated Exposure #1
Prazo: At the end of the baseline assessment

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #2
Prazo: At the end of the baseline assessment

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #3
Prazo: At the end of the baseline assessment

Extent to which claim #3 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #4
Prazo: At the end of the baseline assessment

Extent to which claim #4 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #5
Prazo: At the end of the baseline assessment

Extent to which claim #5 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #6
Prazo: At the end of the baseline assessment

Extent to which claim #6 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #1
Prazo: At the end of the baseline assessment

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #2
Prazo: At the end of the baseline assessment

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #3
Prazo: At the end of the baseline assessment

Extent to which claim #3 made the participants anxious or nervous about the HIV vaccine. TThey were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #4
Prazo: At the end of the baseline assessment

Extent to which claim #4 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #5
Prazo: At the end of the baseline assessment

Extent to which claim #5 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #6
Prazo: At the end of the baseline assessment

Extent to which claim #6 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #1
Prazo: At the end of the baseline assessment

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #7
Prazo: At the end of the baseline assessment

Extent to which claim #7 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #3
Prazo: At the end of the baseline assessment

Extent to which claim #3 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #4
Prazo: At the end of the baseline assessment

Extent to which claim #4 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #5
Prazo: At the end of the baseline assessment

Extent to which claim #5 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #6
Prazo: At the end of the baseline assessment

Extent to which claim #6 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #1, Follow-up
Prazo: 2-4 weeks

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of Inoculated Exposure #2, Follow-up
Prazo: 2-4 weeks

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Shareability of Inoculated Exposure #1, Follow-up
Prazo: 2-4 weeks

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of Inoculated Exposure #2, Follow-up
Prazo: 2-4 weeks

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Anxiousness of Inoculated Exposure #1, Follow-up
Prazo: 2-4 weeks

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of Inoculated Exposure #2, Follow-up
Prazo: 2-4 weeks

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Credibility of New Claims, Exposure #12, Follow-up
Prazo: 2-4 weeks

Extent to which claim #12 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #8, Follow-up
Prazo: 2-4 weeks

Extent to which claim #8 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #9, Follow-up
Prazo: 2-4 weeks

Extent to which claim #9 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #10, Follow-up
Prazo: 2-4 weeks

Extent to which claim #10 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #11, Follow-up
Prazo: 2-4 weeks

Extent to which claim #11 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness o of New Claims, Exposure #12, Follow-up
Prazo: 2-4 weeks

Extent to which claim #12 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Claim #8, Follow-up
Prazo: 2-4 weeks

Extent to which claim #8 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #9, Follow-up
Prazo: 2-4 weeks

Extent to which claim #9 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #10, Follow-up
Prazo: 2-4 weeks

Extent to which claim #10 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #11, Follow-up
Prazo: 2-4 weeks

Extent to which claim #11 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #12, Follow-up
Prazo: 2-4 weeks

Extent to which claim #12 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #8, Follow-up
Prazo: 2-4 weeks

Extent to which claim #8 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #9, Follow-up
Prazo: 2-4 weeks

Extent to which claim #9 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #10, Follow-up
Prazo: 2-4 weeks

Extent to which claim #10 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #11, Follow-up
Prazo: 2-4 weeks

Extent to which claim #11 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Credibility of Inoculated Exposure #7
Prazo: At the end of the baseline assessment

Extent to which claim #7 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #7
Prazo: At the end of the baseline assessment

Extent to which claim #7 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #2
Prazo: At the end of the baseline assessment

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of New Claims, Exposure #13, Follow-up
Prazo: 2-4 weeks

Extent to which claim #13 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness of New Claims, Exposure #13, Follow-up
Prazo: 2-4 weeks

Extent to which claim #13 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #13, Follow-up
Prazo: 2-4 weeks

Extent to which claim #13 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

24 de julho de 2025

Conclusão Primária (Real)

16 de outubro de 2025

Conclusão do estudo (Estimado)

1 de junho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

7 de novembro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de novembro de 2024

Primeira postagem (Real)

22 de novembro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

24 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 1R01MH132401 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

The investigators are still determining the data sharing plan and if we will be sharing IPD yet

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever